OncologyCE
LECTURECME

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

Author(s)/Faculty: Joaquim Bellmunt, MD, PhD; Ravi A. Madan, MD
Release Date: 5/9/2018Expiration Date: 5/8/2019
Credit Type: CMENumber of Credits: 0.5
Content Type: LectureProvider:
The integration of immune checkpoint inhibitors into treatment algorithms for patients with bladder cancer who have failed prior platinum-based chemotherapy or who are ineligible for cisplatin-based chemotherapy have enhanced long-term outcomes and overall survival. As optimal treatment protocols continue to be defined and clinical outcomes from primary studies mature, it is imperative that pertinent reported advances are assessed, refined, and integrated into clinical practice. In this CME activity, experts in the field will review and discuss recent clinical data pertaining to the integration of immune checkpoint inhibitors into treatment algorithms for bladder cancer, including evaluation of potential biomarkers for patient selection, the safety and efficacy of immune checkpoint inhibitors, updated clinical outcomes from primary trials, as well as emerging combination approaches. Presentation of clinical case studies will further provide guidance for the optimal integration of immune checkpoint inhibitors into clinical practice.